Read by QxMD icon Read

Chads vasc score

Sun-Wook Kim, Sol-Ji Yoon, Jung-Yeon Choi, Min-Gu Kang, Kwang-Il Kim, Cheol-Ho Kim
OBJECTIVE: Atrial fibrillation is the common arrhythmia in the elderly, and the average age of atrial fibrillation patients is rising. Elderly patients with atrial fibrillation have high incidence of thromboembolic complication and increasing age is associated with stroke severity. Assessing CHADS-VASc score is pivotal to evaluate substantial morbidity and mortality, especially regarding the increased risk of stroke. In addition, considering bleeding risk with HAS-BLED score is important to balance the benefit against the risk of bleeding...
September 2016: Journal of Hypertension
Victoria Chatzimavridou-Grigoriadou, Prodromos Kanavidis, Alexander G Mathioudakis
No abstract text is available yet for this article.
October 15, 2016: International Journal of Cardiology
Felipe Bisbal, Federico Gómez-Pulido, Pilar Cabanas-Grandío, Nazem Akoum, Mireia Calvo, David Andreu, Susanna Prat-González, Rosario J Perea, Roger Villuendas, Antonio Berruezo, Marta Sitges, Antoni Bayés-Genís, Josep Brugada, Nassir F Marrouche, Lluís Mont
BACKGROUND: Left atrial (LA) sphericity (LASP) is a new remodeling parameter based on LA shape analysis, with independent predictive value for recurrence after atrial fibrillation (AF) ablation. OBJECTIVES: To evaluate the association between LASP and thromboembolic events (TE) in patients with AF. METHODS: Twenty-nine AF patients and prior TE and 29 age- and gender-matched controls were included. LASP was calculated using a 3D-LA reconstruction...
July 2016: Journal of Cardiovascular Electrophysiology
Burak Turan, Hakan Demir, Ayhan Mutlu, Tolga Daşlı, Ayhan Erkol, İsmail Erden
OBJECTIVE: A combination of warfarin and aspirin is associated with increased bleeding compared with warfarin monotherapy. The aim of the study was to investigate the incidence and appropriateness of the combination of warfarin and aspirin in patients with atrial fibrillation (AF) or mechanical heart valve (MHV). METHODS: This cross-sectional study included consecutive patients with AF or MHV on chronic warfarin therapy (>3 months) without acute coronary syndrome or have not undergone a revascularization procedure in the preceding year...
March 2016: Anatolian Journal of Cardiology
Jacqueline Saw, Peter Fahmy, Peggy DeJong, Mathieu Lempereur, Ryan Spencer, Michael Tsang, Kenneth Gin, John Jue, John Mayo, Patrick McLaughlin, Savvas Nicolaou
AIMS: Left atrial appendage (LAA) device imaging after endovascular closure is important to assess for device thrombus, residual leak, positioning, surrounding structures, and pericardial effusion. Cardiac CT angiography (CCTA) is well suited to assess these non-invasively. METHODS AND RESULTS: We report our consecutive series of non-valvular atrial fibrillation patients who underwent CCTA post-LAA closure with Amplatzer Cardiac Plug (ACP), Amulet (second generation ACP), or WATCHMAN devices...
November 2015: European Heart Journal Cardiovascular Imaging
Filip M Szymański, Krzysztof J Filipiak, Anna E Płatek, Marcin Kotkowski, Grzegorz Opolski
BACKGROUND: Erectile dysfunction (ED) is highly prevalent in patients with diseases of cardiovascular system, including patients with atrial fibrillation (AF). Reasons for this high co-prevalence include endothelial dysfunction, inflammation, oxidative and emotional stress associated with AF. Association of AF-induced prothrombotic state and possible microthrombi in penile arteries with ED remains unclear. The present study aims to assess if probability of AF-associated risk of peripheral thromboembolism may be associated with ED in AF patients...
2015: Cardiology Journal
Young Dae Kim, Kyung Yul Lee, Hyo Suk Nam, Sang Won Han, Jong Yun Lee, Han-Jin Cho, Gyu Sik Kim, Seo Hyun Kim, Myoung-Jin Cha, Seong Hwan Ahn, Seung-Hun Oh, Kee Ook Lee, Yo Han Jung, Hye-Yeon Choi, Sang-Don Han, Hye Sun Lee, Chung Mo Nam, Eun Hye Kim, Ki Jeong Lee, Dongbeom Song, Hui-Nam Park, Ji Hoe Heo
PURPOSE: In this study, we investigated the stroke mechanism and the factors associated with ischemic stroke in patients with nonvalvular atrial fibrillation (NVAF) who were on optimal oral anticoagulation with warfarin. MATERIALS AND METHODS: This was a multicenter case-control study. The cases were consecutive patients with NVAF who developed cerebral infarction or transient ischemic attack (TIA) while on warfarin therapy with an international normalized ratio (INR) ≥2 between January 2007 and December 2011...
March 2015: Yonsei Medical Journal
Cho Thae Phyu, Caroline Taylor, Zainab Khan, Richard Cowell
AIM: To improve an appropriate use of antithrombotic therapy in atrial fibrillation (AF) on the basis of the presence (or absence) of stroke risk factors (based on CHA2DS2VASc score) as per ESC guideline. METHOD: This was a retrospective audit and data was obtained from the health record department on the total number of stroke admissions in 2012. A proforma based on the ECS guide was created and used to collect data from those that were coded as having a diagnosis of AF alongside the CVA...
June 2014: Heart: Official Journal of the British Cardiac Society
Kui-Kai Lau, Pak-Hei Chan, Kai-Hang Yiu, Yap-Hang Chan, Shasha Liu, Koon-Ho Chan, Chun-Yip Yeung, Sheung-Wai Li, Hung-Fat Tse, Chung-Wah Siu
BACKGROUND: Patients with myocardial infarction (MI) are at risk of the development of atrial fibrillation (AF) and ischemic stroke. We sought to evaluate the prognostic performance of the CHADS₂ and CHA₂DS₂-VASc scores in predicting new AF and/or ischemic stroke in post-ST segment elevation MI (STEMI) patients. Six hundred and seven consecutive post-STEMI patients with no previously documented AF were studied. METHODS AND RESULTS: After a follow-up of 63 months (3,184 patient-years), 83 (13...
2014: Cardiology Journal
Chia-Ti Tsai, Shu-Hsuan Chang, Sheng-Nan Chang, Juey-Jen Hwang, Cho-Kai Wu, Yi-Chih Wang, Chuen-Den Tseng, Huei-Ming Yeh, Ling-Ping Lai, Fu-Tien Chiang, Jiunn-Lee Lin
BACKGROUND: The CHA₂DS₂-VASC scoring scheme may not be better than the CHADS₂ scoring scheme in predicting thromboembolic risk for patients with atrial fibrillation (AF) in Asians. Metabolic syndrome is associated with an increased risk of thrombosis. OBJECTIVE: To evaluate whether metabolic syndrome offers incremental information over the CHADS₂ scheme in predicting thromboembolic risk for patients with AF in the Taiwanese population. METHODS: The study population consisted of 721 consecutive patients with AF who had been followed up for a median of 10...
March 2014: Heart Rhythm: the Official Journal of the Heart Rhythm Society
V E Held, M E Wolf, M G Hennerici
Historically, studies of antithrombotic therapy in ischemic cerebrovascular disease have included both stroke and transient ischemic attack (TIA). Thus, therapy regimes are very similar. Aspirin (75-325 mg within 48 h after onset of symptoms) is still the standard antithrombotic treatment because other agents have performed similarly (or worse). Combinations of agents have shown mixed results. Aspirin combined with clopidogrel has failed to show a significant reduction of stroke/TIA recurrences but increased the bleeding risk if taken for more than several months...
2014: Frontiers of Neurology and Neuroscience
Janusz Bednarski, Ewa Cieszewska, Aleksander Strzelecki, Krzysztof J Filipiak
BACKGROUND AND AIM: Retrospective evaluation of stroke risk in all patients with atrial fibrillation (AF) admitted to cardiology, internal medicine, and neurology wards in a single Polish district hospital in 2006 and 2010 using two risk stratification schemes, CHADS₂ vs. CHA₂DS₂VASc risk scores and identification of independent predictors of guideline-compliant oral anticoagulant (OAC) treatment. METHODS: We analysed case records of 613 patients with AF (including 300 patients in 2006 and 313 patients in 2010) treated in a district hospital - the John Paul II Western Hospital (Szpital Zachodni) in Grodzisk Mazowiecki, to evaluate their stroke risk and therapy prescribed at discharge...
2013: Kardiologia Polska
David E Haines, Michelle Mead-Salley, Miguel Salazar, Francis E Marchlinski, Erica Zado, Hugh Calkins, Hirad Yarmohammadi, Koonlawee Nademanee, Montawatt Amnueypol, Allan C Skanes, Pradyot Saklani
BACKGROUND: Systemic thromboembolism and bleeding remain the two most common and serious complications of catheter ablation of atrial fibrillation. A variety of periprocedure anticoagulation strategies have been proposed to mitigate these risks. Although operators are now routinely administering dabigatran for anticoagulation in this setting, its relative safety and effectiveness compared to warfarin are unknown. METHODS AND RESULTS: A total of 202 patients received dabigatran as part of their periprocedural anticoagulation regimen at the time of initial or redo catheter ablation for symptomatic atrial fibrillation...
September 2013: Journal of Interventional Cardiac Electrophysiology: An International Journal of Arrhythmias and Pacing
Julie K Atay, John Fanikos, Geoffrey D Barnes, Michael Ehle, John Coatney, Gregory Piazza, James B Froehlich, Samuel Z Goldhaber
Dabigatran was expected to replace warfarin for stroke prevention in patients with nonvalvular atrial fibrillation (AF) who are warfarin naive, difficult to maintain in therapeutic range, or at risk of warfarin-related bleeding complications. We hypothesized that the number of patients with nonvalvular AF referred to Anticoagulation Management Services would decrease sharply and that most would switch from warfarin to dabigatran. We evaluated the number of patients with nonvalvular AF referred to 2 large services, Anticoagulation Management Service 1 and Anticoagulation Management Service 2, 12 months before and after market entry of dabigatran...
August 1, 2013: American Journal of Cardiology
Vivek Y Reddy, Sven Möbius-Winkler, Marc A Miller, Petr Neuzil, Gerhard Schuler, Jens Wiebe, Peter Sick, Horst Sievert
OBJECTIVES: The purpose of this study was to assess the safety and efficacy of left atrial appendage (LAA) closure in nonvalvular atrial fibrillation (AF) patients ineligible for warfarin therapy. BACKGROUND: The PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) trial demonstrated that LAA closure with the Watchman device (Boston Scientific, Natick, Massachusetts) was noninferior to warfarin therapy. However, the PROTECT AF trial only included patients who were candidates for warfarin, and even patients randomly assigned to the LAA closure arm received concomitant warfarin for 6 weeks after Watchman implantation...
June 25, 2013: Journal of the American College of Cardiology
Tiago Sá, João Sargento-Freitas, Vítor Pinheiro, Rui Martins, Rogério Teixeira, Fernando Silva, Nuno Mendonça, Gustavo Cordeiro, Lino Gonçalves, Luís A Providência, António Freire-Gonçalves, Luís Cunha
INTRODUCTION AND OBJECTIVES: Cardioembolism is one of the most common causes of ischemic stroke, with an estimated prevalence of 20-30%, and correct diagnosis is essential given the therapeutic implications. Although stroke risk scores (CHADS2 and more recently CHA2DS2-VASc) have been validated in heterogeneous populations of patients with atrial fibrillation, their accuracy has not been ascertained for secondary stroke prevention. We set out to assess the sensitivity and specificity of the CHADS2 and CHA2DS2-VASc stroke risk scores as predictors of cardioembolic sources, documented by transesophageal echocardiography (TEE) in a population with ischemic stroke...
May 2013: Portuguese Journal of Cardiology: An Official Journal of the Portuguese Society of Cardiology
M K Freynhofer, D F Draxler, S C Gruber, V Bruno, T Höchtl, B Fellner, G Jakl-Kotauschek, J Wojta, I Pabinger-Fasching, K Huber, C Ay
BACKGROUND: Atrial fibrillation (AF) is associated with raised levels of P-selectin and an apparent prothrombotic state. However, levels of tissue plasminogen activator (t-PA)-antigen are increased also. We investigated whether high levels of endogenous t-PA-antigen or soluble P-Selectin (sP-Selectin), independently of CHADS(2-) or CHA(2) DS(2) VASc-scores, predict major adverse cardiovascular events (MACE) in patients with AF when treated according to current guidelines. METHODS: This prospective, longitudinal single-center study included 269 patients with AF...
June 2013: Journal of Thrombosis and Haemostasis: JTH
Amitava Banerjee, Laurent Fauchier, Patrick Vourc'h, Christian R Andres, Sophie Taillandier, Jean Michel Halimi, Gregory Y H Lip
OBJECTIVES: This study sought to determine the risk of ischemic stroke (IS)/thromboembolism (TE) associated with renal impairment and its incremental predictive value over established risk stratification scores (congestive heart failure, hypertension, age ≥75 years, diabetes, previous stroke [CHADS2] and congestive heart failure, hypertension, age ≥75 years, diabetes, previous stroke, vascular disease, age 65 to 74 years, sex category (female) [CHA₂DS₂-VASc]) in patients with atrial fibrillation (AF)...
May 21, 2013: Journal of the American College of Cardiology
George Ntaios, Gregory Y H Lip, Konstantinos Makaritsis, Vasileios Papavasileiou, Anastasia Vemmou, Eleni Koroboki, Paraskevi Savvari, Efstathios Manios, Haralampos Milionis, Konstantinos Vemmos
OBJECTIVE: CHADS2 and CHA2DS2-VASc scores are used to assess stroke risk in patients with atrial fibrillation (AF). We investigated whether these scores are associated with stroke outcome in non-AF stroke patients. METHODS: Consecutive patients with acute first-ever ischemic stroke but without AF were classified into subgroups according to prestroke CHADS2 and CHA2DS2-VASc scores and followed up for 5 years. The end points were death, stroke recurrence, and a composite of major cardiovascular events...
March 12, 2013: Neurology
Gregory Y H Lip, Stuart Connolly, Salim Yusuf, Olga Shestakovska, Greg Flaker, Robert Hart, Fernando Lanas, Denis Xavier, John Eikelboom
BACKGROUND: The impact of apixaban versus aspirin on ischemic stroke and major bleeding in relation to the CHADS(2) and CHA(2)DS(2)-VASc stroke risk scores in atrial fibrillation has not been investigated. METHODS AND RESULTS: In this secondary analysis of the AVERROES trial, our principal objective was to assess the effect of treatment with aspirin or apixaban on ischemic stroke and major bleeding, in relation to the CHADS(2)/CHA(2)DS(2)-VASc scores. We found no significant heterogeneity for treatment efficacy on ischemic stroke for apixaban when subdivided by stroke risk strata, based on CHADS(2)/CHA(2)DS(2)-VASc...
February 2013: Circulation. Arrhythmia and Electrophysiology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"